|
 
- 现金
- 17064 元
- 精华
- 12
- 帖子
- 9399
- 注册时间
- 2007-6-26
- 最后登录
- 2017-11-25
|
Arrowhead to Present at Upcoming Conferences
PASADENA, Calif.--(BUSINESS WIRE)-- Arrowhead Research Corporation (NASDAQ: ARWR), a biopharmaceutical company developing targeted RNAi therapeutics, today announced that the company will make presentations at the following upcoming events.
The Liver Meeting 2015®, 66th Annual Meeting of the American Association for the Study of Liver Disease (AASLD) - San Francisco, November 13-17, 2015
November 15, 3:15 p.m. PST - Christine Wooddell, Ph.D., Arrowhead group leader will deliver an oral presentation titled, "Reductions in cccDNA under NUC and ARC-520 therapy in chimpanzees with chronic hepatitis B virus infection implicate integrated DNA in maintaining circulating HBsAg"November 16, 8:00 a.m. - 5:30 p.m. PST - Man-Fung Yuen, M.D., Ph.D., chair of gastroenterology and hepatology, The University of Hong Kong, and deputy chief of service, Queen Mary Hospital department of medicine, Hong Kong, will deliver a late-breaking poster presentation titled, "ARC-520 produces deep and durable knockdown of viral antigens and DNA in a phase II study in patients with chronic hepatitis B"
November 16, 6:30 p.m. PST - Arrowhead management will host an Analyst and Investor Reception to discuss ARC-520 and key data being presented at the conference
November 17, 8:00 a.m. - 12:00 p.m. PST - Christine Wooddell, Ph.D., Arrowhead group leader will deliver a poster presentation titled, "Monthly dosing of ARC-520 in chronically hepatitis B virus infected chimpanzees produces rapid, deep and durable reductions in circulating viral antigens"Jefferies Autumn 2015 Global Healthcare Conference - London, UK, November 18-19, 2015
November 19, 2:40 p.m. GMT - Chris Anzalone, Ph.D., Arrowhead president and chief executive officer, will present a company overviewPiper Jaffray 27th Annual Healthcare Conference - New York, December 1-2, 2015
December 2, 3:00 p.m. EST - Chris Anzalone, Ph.D., Arrowhead president and chief executive officer, will present a company overview in a fireside chat with Ted Tenthoff, senior research analyst, Piper JaffrayHEP DART 2015 - Wailea, Hawaii, December 6-10, 2015
December 2, 6:40 p.m. HST - Bruce Given, M.D., Arrowhead chief operating officer, will deliver an oral presentation titled, "New insights on HBV biology from the ARC-520 development program"December 8, 4:00 - 5:30 p.m. HST - Christine Wooddell, Ph.D., Arrowhead group leader will deliver a poster presentation titled, "Sustained reduction in HBsAg, HBV DNA and HBeAg seroconversion in a chronically HBV-infected chimpanzee treated with nucleoside analog/ARC-520 combination therapy" |
|
楼主: ivanich
发表于 2015-11-15 13:13
